BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36787255)

  • 21. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineered proteins with sensing and activating modules for automated reprogramming of cellular functions.
    Sun J; Lei L; Tsai CM; Wang Y; Shi Y; Ouyang M; Lu S; Seong J; Kim TJ; Wang P; Huang M; Xu X; Nizet V; Chien S; Wang Y
    Nat Commun; 2017 Sep; 8(1):477. PubMed ID: 28883531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
    Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
    Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phagocytosis checkpoints as new targets for cancer immunotherapy.
    Feng M; Jiang W; Kim BYS; Zhang CC; Fu YX; Weissman IL
    Nat Rev Cancer; 2019 Oct; 19(10):568-586. PubMed ID: 31462760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.
    Logtenberg MEW; Jansen JHM; Raaben M; Toebes M; Franke K; Brandsma AM; Matlung HL; Fauster A; Gomez-Eerland R; Bakker NAM; van der Schot S; Marijt KA; Verdoes M; Haanen JBAG; van den Berg JH; Neefjes J; van den Berg TK; Brummelkamp TR; Leusen JHW; Scheeren FA; Schumacher TN
    Nat Med; 2019 Apr; 25(4):612-619. PubMed ID: 30833751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
    Matozaki T; Murata Y; Okazawa H; Ohnishi H
    Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era.
    Montero E; Isenberg JS
    Cancer Immunol Immunother; 2023 Sep; 72(9):2879-2888. PubMed ID: 37217603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-SIRP
    Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
    JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
    Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
    Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
    Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
    Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
    Bouwstra R; van Meerten T; Bremer E
    Clin Transl Med; 2022 Aug; 12(8):e943. PubMed ID: 35908284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
    Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
    Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPα (signal regulatory protein-α) on phagocytes.
    Gitik M; Liraz-Zaltsman S; Oldenborg PA; Reichert F; Rotshenker S
    J Neuroinflammation; 2011 Mar; 8():24. PubMed ID: 21401967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis.
    Yang H; Shao R; Huang H; Wang X; Rong Z; Lin Y
    Cancer Med; 2019 Aug; 8(9):4245-4253. PubMed ID: 31183992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD47: role in the immune system and application to cancer therapy.
    Hayat SMG; Bianconi V; Pirro M; Jaafari MR; Hatamipour M; Sahebkar A
    Cell Oncol (Dordr); 2020 Feb; 43(1):19-30. PubMed ID: 31485984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.